Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries

By LabMedica International staff writers
Posted on 15 Mar 2024

Tuberculosis (TB) is one of the top infectious killers worldwide, second only to COVID-19. Keeping track of how well treatment works is key to fighting this disease. However, testing TB samples is tricky because it's highly infectious, requiring special high-security labs known as biosafety level 3 (BSL-3) labs. These labs have special equipment to keep the virus from spreading, but they're expensive and hard to find, especially in low- and middle-income countries where most TB cases are found. This makes fighting TB difficult in the places that need it most. Now, a new test allows testing for TB treatment monitoring to be done outside of a BSL-3 laboratory, potentially making it easier and faster to treat TB worldwide.

The new TB test — called rapid enumeration and diagnostic for tuberculosis (READ-TB) — was disclosed in the Association for Diagnostics & Laboratory Medicine's (ADLM, Washington, DC, USA) Clinical Chemistry journal and has been designed specifically to address the lack of access to labs that meet BSL-3 requirements. The test works by treating sputum (lung mucus coughed up by patients) with acetic acid. This acid kills the TB bacteria but leaves their RNA (genetic material) untouched. A lab worker can then safely check the RNA levels with a machine, which tells how much TB bacteria is in the patient and how well the treatment is working.

Acetic acid is better at preserving RNA than the current gold standard of using guanidium salts for two reasons: it kills the bacteria in just 30 minutes, thus eliminating the need for a BSL-3 lab, and it's just as effective at keeping the RNA safe. The RNA remains stable for 14 days at room temperature and for over a year if frozen at -20°C. This is ideal for labs without the capacity for super-cold storage. Plus, acetic acid is less toxic than guanidium salts, making it safer for lab workers. The READ-TB test isn't just safer and easier; it could also help with TB drug research. By accurately measuring TB RNA levels, scientists can compare different TB drugs or drug combinations more effectively.

"We wanted to improve the assay for integration into diagnostic microbiology laboratories, for use in clinical trials, and to make it tenable in low- and middle-income countries, e.g., where no BSL-3 laboratory exists," the authors of the study write, referring to their earlier test. "READ-TB allows measurement of the molecular bacterial load to now be adopted by routine clinical microbiology laboratories for measuring M. tuberculosis bacterial load in sputum."

Related Links:
ADLM

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.